16.4 C
New York
Tuesday, June 9, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1marketreleases

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

New Report Reveals 3 in 4 CRNAs Got a Raise Last Year While Most Remain Just One Good Offer Away from a Career Move

CHARLOTTE, N.C., June 3, 2026 /PRNewswire/ -- APEX Anesthesia Review, a TrueLearn brand, surveyed 634 Certified Registered Nurse Anesthetists (CRNAs) and Student Registered Nurse...

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting

GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance

ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its acquisition of Family First Holding, LLC ("Family First Homecare").

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

Philips announces exchange ratio for 2025 dividend

June 2, 2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers